Rare Disease Trial, Recruiting (NCT05773651)

Rare Disease Trial, Recruiting NCT05773651 Sponsor: University Hospital Tuebingen Condition: Rare Disease

Printed from Voxsanity (voxsanity.com.au) — NCT05773651 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Rare Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You or your child has been diagnosed with a rare solid tumor (a type of cancer that forms a solid mass, rather than blood cancer)
The person diagnosed was between newborn age and 18 years old at the time of diagnosis (in some cases, young adults may also be able to register — ask the trial site for details)
The patient or their parent/guardian has been given information about the study and has signed a written consent form agreeing to take part
The patient is not already registered in any existing clinical studies or registries run by the German Society for Pediatric Oncology and Hematology (GPOH)

Who may not be able to join:

The patient's tumor diagnosis is already registered in another active treatment study or clinical registry run by the GPOH
The patient or their parent/guardian has not received proper information about the study, or has not given written consent to participate

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Ines Brecht, PD Dr. med., University Hospital Tübingen

Phone: +49 7071 29

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05773651

Sponsor: University Hospital Tuebingen

Phase: Not Applicable

Status: Recruiting

Condition: Rare Disease

Trial contact: +49 7071 29

More information: https://clinicaltrials.gov/study/NCT05773651

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You or your child has been diagnosed with a rare solid tumor (a type of cancer that forms a solid mass, rather than blood cancer)
The person diagnosed was between newborn age and 18 years old at the time of diagnosis (in some cases, young adults may also be able to register — ask the trial site for details)
The patient or their parent/guardian has been given information about the study and has signed a written consent form agreeing to take part
The patient is not already registered in any existing clinical studies or registries run by the German Society for Pediatric Oncology and Hematology (GPOH)

Who may not be able to join:

The patient's tumor diagnosis is already registered in another active treatment study or clinical registry run by the GPOH
The patient or their parent/guardian has not received proper information about the study, or has not given written consent to participate

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

University Hospital Tuebingen

Registry

ClinicalTrials.gov

Start date

11 January 2023

Est. completion

1 January 2050

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

Event-free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov